Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.08% | 26.98% | 21.32% | -5.84% | -10.70% |
| Gross Profit | -16.08% | -26.98% | -21.40% | 3.84% | 8.44% |
| SG&A Expenses | 26.53% | 20.51% | 13.73% | -8.76% | -10.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.01% | 22.88% | 18.16% | 16.56% | 12.53% |
| Operating Income | -18.01% | -22.88% | -18.21% | -18.38% | -14.62% |
| Income Before Tax | -34.24% | -71.01% | -57.49% | -263.22% | -825.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.24% | -71.01% | -57.49% | -263.22% | -825.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.24% | -71.01% | -57.49% | -263.22% | -825.83% |
| EBIT | -18.01% | -22.88% | -18.21% | -18.38% | -14.62% |
| EBITDA | -20.16% | -26.01% | -21.20% | -21.39% | -16.83% |
| EPS Basic | -17.93% | -54.99% | -47.09% | -257.95% | -822.74% |
| Normalized Basic EPS | -3.03% | -15.09% | -13.70% | -15.87% | -11.69% |
| EPS Diluted | -17.93% | -54.99% | -47.09% | -248.19% | -763.95% |
| Normalized Diluted EPS | -3.03% | -15.09% | -13.70% | -16.09% | -11.90% |
| Average Basic Shares Outstanding | 14.54% | 9.00% | 5.25% | 1.50% | 0.36% |
| Average Diluted Shares Outstanding | 14.54% | 9.00% | 5.25% | 1.28% | 0.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |